Condition

Primary Central Nervous System Lymphoma (PCNSL) clinical trials and research

• 11Clinical trials
• 9Countries

Newest Primary Central Nervous System Lymphoma (PCNSL) clinical trials

All recruiting trials (11)

• Biobank Registry for Primary CNS Lymphoma in China

  This study will collect and register a long-term, multimodal biobank from adults with PCNSL to support future research, using patients with similar diagnoses as controls and healthy volunteers for comparison.

  Recruiting at 3 sites Beijing Tiantan Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07842835

• Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL

  This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.

  Recruiting Phase 2 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07839247

• Pomalidomide, anti–PD‑1 antibody, and selinexor for relapsed/refractory primary CNS diffuse large B‑cell lymphoma

  This trial tests whether combining pomalidomide, a PD‑1 blocking antibody, and selinexor can help adults with relapsed or refractory primary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07523737

• PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib for newly diagnosed primary or secondary CNS lymphoma

  This trial will test whether combining a PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib helps people with newly diagnosed primary or secondary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07410520

• Comparing metabolic and immune profiles in primary CNS diffuse large B‑cell lymphoma

  This study will test whether people with primary CNS diffuse large B‑cell lymphoma have different metabolic and immune patterns compared with lymphoma patients without CNS involvement and with healthy donors.

  Recruiting Fujian Medical University · Fuzhou, Fujian · NCT07188077

• Epcoritamab plus ibrutinib for central nervous system lymphoma

  This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

• Teniposide plus PD-1 antibody and selinexor for relapsed or refractory primary CNS lymphoma

  This study will test whether combining teniposide, a PD‑1 antibody, and selinexor can shrink tumors and control disease in adults 18–75 with relapsed or refractory primary central nervous system lymphoma after high‑dose methotrexate.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07074470

• High-dose gemcitabine, busulfan, and thiotepa with autologous stem cell transplant for primary central nervous system lymphoma.

  This trial tests if giving high-dose gemcitabine, busulfan, and thiotepa before an autologous stem cell transplant is safe and helps control primary CNS lymphoma in adults who are in remission or have a partial response.

  Recruiting Phase 2 Sichuan University · Chengdu, Sichuan · NCT07014943

• New treatment approach for primary central nervous system lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed primary central nervous system lymphoma to see if it can help them respond better and stay healthy longer.

  Recruiting The First Hospital of Jilin University · Changchun · NCT06946407

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

Related topics

Quick answers

How many Primary Central Nervous System Lymphoma (PCNSL) clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in China (8 trials), United States (3 trials), France (1 trial), Italy (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →